Gemina Laboratories (XCNQ:GLAB) Accounts Receivable : C$0.00 Mil (As of Jan. 2024)

View and export this data going back to 2021. Start your Free Trial

What is Gemina Laboratories Accounts Receivable?

Accounts Receivable are created when a customer has received a product but has not yet paid for that product. Gemina Laboratories's accounts receivables for the quarter that ended in Jan. 2024 was C$0.00 Mil.

Accounts receivable can be measured by Days Sales Outstanding.

In Ben Graham's calculation of Net-Net Working Capital, accounts receivable are only considered to be worth 75% of book value. Gemina Laboratories's Net-Net Working Capital per share for the quarter that ended in Jan. 2024 was C$-0.04.

Gemina Laboratories Accounts Receivable Historical Data

The historical data trend for Gemina Laboratories's Accounts Receivable can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Gemina Laboratories Accounts Receivable Chart

Gemina Laboratories Annual Data

Trend

Jan21

Jan22

Jan23

Jan24

Accounts Receivable

Gemina Laboratories Quarterly Data
	Apr21	Jul21	Oct21	Jan22	Apr22	Jul22	Oct22	Jan23	Apr23	Jul23	Oct23	Jan24
Accounts Receivable	Get a 7-Day Free Trial							-	-	-	-	-

Gemina Laboratories Accounts Receivable Calculation

Accounts Receivable is money owed to a business by customers and shown on its Balance Sheet as an asset.

Gemina Laboratories Accounts Receivable Explanation

1. Accounts Receivable are created when a customer has received a product but has not yet paid for that product. Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's accounts receivables are being managed.

Gemina Laboratories's Days Sales Outstanding for the quarter that ended in Jan. 2024 is calculated as:

	Days Sales Outstanding
=	Accounts Receivable	/	Revenue	*	Days in Period
=	0	/	0	*	91
=

2. In Ben Graham's calculation of Net-Net Working Capital (NNWC), Gemina Laboratories's accounts receivable are only considered to be worth 75% of book value:

Gemina Laboratories's Net-Net Working Capital Per Share for the quarter that ended in Jan. 2024 is calculated as:

	Net-Net Working Capital Per Share
=	(Cash And Cash Equivalents	+	0.75 * Accounts Receivable	+	0.5 * Total Inventories	-	Total Liabilities
-	Preferred Stock	-	Minority Interest)	/	Shares Outstanding (EOP)
=	(0.001	+	0.75 * 0	+	0.5 * 0	-	3.041
-	0	-	0)	/	73.3259
=	-0.04

Be Aware

Net receivables tells us a great deal about the different competitors in the same industry. In competitive industries, some attempt to gain advantage by offering better credit terms, causing increase in sales and receivables.

If company consistently shows lower % Net receivables to gross sales than competitors, then it usually has some kind of competitive advantage which requires further digging.

Average Days Sales Outstanding is a good indicator for measuring a company's sales channel and customers. A company may book great revenue and earnings growth but never receive payment from their customers. This may force a write-off in the future and depress future earnings.

Gemina Laboratories Accounts Receivable Related Terms

Thank you for viewing the detailed overview of Gemina Laboratories's Accounts Receivable provided by GuruFocus.com. Please click on the following links to see related term pages.

Gemina Laboratories (XCNQ:GLAB) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Gemina Laboratories Ltd (XCNQ:GLAB) » Definitions » Accounts Receivable

Comparable Companies

Traded in Other Exchanges

GLABF:USA

Address

3800 Gilmore Mall, Suite 302, Burnaby, BC, CAN, V5G 4R8

Website

https://www.geminalabs.com

Gemina Laboratories Ltd is a biotechnology company that operates in the In Vitro Diagnostics (IVD) market under the name Gemina Labs. The company endeavors to develop novel surface functionalization chemistries for the detection of pathogens and biomarkers.

Executives

James Damian Tansey

Director

Gemina Laboratories (XCNQ:GLAB) Headlines

No Headlines